nodes	percent_of_prediction	percent_of_DWPC	metapath
Raloxifene—CYP2C8—Vismodegib—skin cancer	0.178	0.297	CbGbCtD
Raloxifene—CYP3A4—Imiquimod—skin cancer	0.104	0.174	CbGbCtD
Raloxifene—CYP3A4—Temozolomide—skin cancer	0.104	0.174	CbGbCtD
Raloxifene—CYP3A4—Vismodegib—skin cancer	0.072	0.121	CbGbCtD
Raloxifene—CYP2C8—Fluorouracil—skin cancer	0.0631	0.106	CbGbCtD
Raloxifene—CYP3A4—Vemurafenib—skin cancer	0.0569	0.0954	CbGbCtD
Raloxifene—CYP3A4—Docetaxel—skin cancer	0.0195	0.0327	CbGbCtD
Raloxifene—Dyclonine—SCN10A—skin cancer	0.0144	1	CrCbGaD
Raloxifene—EBP—Sorafenib—Vismodegib—skin cancer	0.00896	1	CbGdCrCtD
Raloxifene—EBP—female reproductive system—skin cancer	0.00322	0.0794	CbGeAlD
Raloxifene—Gastrointestinal symptom NOS—Fluorouracil—skin cancer	0.00304	0.00896	CcSEcCtD
Raloxifene—Connective tissue disorder—Vismodegib—skin cancer	0.00303	0.00894	CcSEcCtD
Raloxifene—Embolism—Temozolomide—skin cancer	0.00302	0.00891	CcSEcCtD
Raloxifene—Arthritis—Vemurafenib—skin cancer	0.00283	0.00836	CcSEcCtD
Raloxifene—Tenderness—Bleomycin—skin cancer	0.00264	0.00777	CcSEcCtD
Raloxifene—Vaginal haemorrhage—Temozolomide—skin cancer	0.00262	0.00773	CcSEcCtD
Raloxifene—Muscle spasms—Vismodegib—skin cancer	0.00258	0.00761	CcSEcCtD
Raloxifene—Arthritis—Imiquimod—skin cancer	0.00242	0.00713	CcSEcCtD
Raloxifene—Cerebrovascular accident—Imiquimod—skin cancer	0.0024	0.00707	CcSEcCtD
Raloxifene—Migraine—Imiquimod—skin cancer	0.00231	0.00682	CcSEcCtD
Raloxifene—Myalgia—Vismodegib—skin cancer	0.00229	0.00674	CcSEcCtD
Raloxifene—Arthralgia—Vismodegib—skin cancer	0.00229	0.00674	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.00227	0.0067	CcSEcCtD
Raloxifene—Cystitis noninfective—Bleomycin—skin cancer	0.00225	0.00662	CcSEcCtD
Raloxifene—Breast pain—Temozolomide—skin cancer	0.00222	0.00656	CcSEcCtD
Raloxifene—Cystitis—Bleomycin—skin cancer	0.00222	0.00655	CcSEcCtD
Raloxifene—ESR2—neck—skin cancer	0.00222	0.0547	CbGeAlD
Raloxifene—AOX1—nipple—skin cancer	0.00216	0.0532	CbGeAlD
Raloxifene—Nervous system disorder—Vismodegib—skin cancer	0.00215	0.00634	CcSEcCtD
Raloxifene—Skin disorder—Vismodegib—skin cancer	0.00213	0.00628	CcSEcCtD
Raloxifene—Breast disorder—Imiquimod—skin cancer	0.00212	0.00626	CcSEcCtD
Raloxifene—ESR1—blood vessel—skin cancer	0.00212	0.0523	CbGeAlD
Raloxifene—Deep vein thrombosis—Docetaxel—skin cancer	0.00212	0.00625	CcSEcCtD
Raloxifene—Bladder pain—Bleomycin—skin cancer	0.00208	0.00613	CcSEcCtD
Raloxifene—Tenderness—Fluorouracil—skin cancer	0.00205	0.00604	CcSEcCtD
Raloxifene—Influenza—Imiquimod—skin cancer	0.00203	0.00599	CcSEcCtD
Raloxifene—Embolism—Docetaxel—skin cancer	0.00201	0.00593	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Vismodegib—skin cancer	0.002	0.00589	CcSEcCtD
Raloxifene—Bronchitis—Imiquimod—skin cancer	0.00195	0.00576	CcSEcCtD
Raloxifene—Vaginal inflammation—Temozolomide—skin cancer	0.00194	0.00572	CcSEcCtD
Raloxifene—Pulmonary embolism—Temozolomide—skin cancer	0.00194	0.00572	CcSEcCtD
Raloxifene—Dyspepsia—Vismodegib—skin cancer	0.00193	0.00569	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Vismodegib—skin cancer	0.00189	0.00558	CcSEcCtD
Raloxifene—Oedema peripheral—Vemurafenib—skin cancer	0.00188	0.00554	CcSEcCtD
Raloxifene—Pain—Vismodegib—skin cancer	0.00187	0.00553	CcSEcCtD
Raloxifene—Connective tissue disorder—Vemurafenib—skin cancer	0.00187	0.00552	CcSEcCtD
Raloxifene—Neuralgia—Docetaxel—skin cancer	0.00186	0.00548	CcSEcCtD
Raloxifene—Vaginal infection—Temozolomide—skin cancer	0.00183	0.0054	CcSEcCtD
Raloxifene—Depression—Imiquimod—skin cancer	0.00181	0.00532	CcSEcCtD
Raloxifene—Gastrointestinal pain—Vismodegib—skin cancer	0.00179	0.00529	CcSEcCtD
Raloxifene—Cardiac disorder—Vemurafenib—skin cancer	0.00177	0.00522	CcSEcCtD
Raloxifene—Conjunctivitis—Imiquimod—skin cancer	0.00176	0.00519	CcSEcCtD
Raloxifene—Urinary tract infection—Imiquimod—skin cancer	0.00176	0.00519	CcSEcCtD
Raloxifene—SIGMAR1—nipple—skin cancer	0.00174	0.0428	CbGeAlD
Raloxifene—Abdominal pain—Vismodegib—skin cancer	0.00173	0.00511	CcSEcCtD
Raloxifene—Angiopathy—Vemurafenib—skin cancer	0.00173	0.0051	CcSEcCtD
Raloxifene—Arthritis—Bleomycin—skin cancer	0.00172	0.00506	CcSEcCtD
Raloxifene—Cerebrovascular accident—Bleomycin—skin cancer	0.0017	0.00502	CcSEcCtD
Raloxifene—Sinusitis—Imiquimod—skin cancer	0.0017	0.00501	CcSEcCtD
Raloxifene—Rhinitis—Imiquimod—skin cancer	0.00163	0.00481	CcSEcCtD
Raloxifene—Pharyngitis—Imiquimod—skin cancer	0.00161	0.00476	CcSEcCtD
Raloxifene—Urinary tract disorder—Imiquimod—skin cancer	0.0016	0.00473	CcSEcCtD
Raloxifene—Connective tissue disorder—Imiquimod—skin cancer	0.0016	0.00471	CcSEcCtD
Raloxifene—Urethral disorder—Imiquimod—skin cancer	0.00159	0.0047	CcSEcCtD
Raloxifene—ESR2—connective tissue—skin cancer	0.00159	0.0392	CbGeAlD
Raloxifene—Gastroenteritis—Temozolomide—skin cancer	0.00159	0.00468	CcSEcCtD
Raloxifene—ESR1—neck—skin cancer	0.00152	0.0374	CbGeAlD
Raloxifene—ESR2—epithelium—skin cancer	0.00151	0.0372	CbGeAlD
Raloxifene—Flushing—Imiquimod—skin cancer	0.00151	0.00445	CcSEcCtD
Raloxifene—Hot flush—Temozolomide—skin cancer	0.0015	0.00444	CcSEcCtD
Raloxifene—Diarrhoea—Vismodegib—skin cancer	0.0015	0.00442	CcSEcCtD
Raloxifene—Menopausal symptoms—Temozolomide—skin cancer	0.00149	0.0044	CcSEcCtD
Raloxifene—Angiopathy—Imiquimod—skin cancer	0.00147	0.00435	CcSEcCtD
Raloxifene—Cough—Vemurafenib—skin cancer	0.00145	0.00427	CcSEcCtD
Raloxifene—Arthralgia—Vemurafenib—skin cancer	0.00141	0.00417	CcSEcCtD
Raloxifene—Myalgia—Vemurafenib—skin cancer	0.00141	0.00417	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.0014	0.00414	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Dactinomycin—skin cancer	0.0014	0.00413	CcSEcCtD
Raloxifene—Vomiting—Vismodegib—skin cancer	0.00139	0.00411	CcSEcCtD
Raloxifene—Rash—Vismodegib—skin cancer	0.00138	0.00408	CcSEcCtD
Raloxifene—Dermatitis—Vismodegib—skin cancer	0.00138	0.00407	CcSEcCtD
Raloxifene—Infection—Vemurafenib—skin cancer	0.00135	0.00397	CcSEcCtD
Raloxifene—HTR6—head—skin cancer	0.00133	0.0329	CbGeAlD
Raloxifene—Nervous system disorder—Vemurafenib—skin cancer	0.00133	0.00392	CcSEcCtD
Raloxifene—Skin disorder—Vemurafenib—skin cancer	0.00132	0.00388	CcSEcCtD
Raloxifene—Nausea—Vismodegib—skin cancer	0.0013	0.00384	CcSEcCtD
Raloxifene—Pneumonia—Bleomycin—skin cancer	0.00129	0.00382	CcSEcCtD
Raloxifene—Blood pressure increased—Docetaxel—skin cancer	0.00129	0.0038	CcSEcCtD
Raloxifene—Pulmonary embolism—Docetaxel—skin cancer	0.00129	0.0038	CcSEcCtD
Raloxifene—Breast disorder—Temozolomide—skin cancer	0.00127	0.00375	CcSEcCtD
Raloxifene—Syncope—Imiquimod—skin cancer	0.00127	0.00374	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Temozolomide—skin cancer	0.00127	0.00374	CcSEcCtD
Raloxifene—AOX1—mammalian vulva—skin cancer	0.00126	0.0311	CbGeAlD
Raloxifene—CYP19A1—connective tissue—skin cancer	0.00125	0.0309	CbGeAlD
Raloxifene—Loss of consciousness—Imiquimod—skin cancer	0.00124	0.00367	CcSEcCtD
Raloxifene—Cough—Imiquimod—skin cancer	0.00123	0.00364	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00123	0.00364	CcSEcCtD
Raloxifene—Pneumonia—Dactinomycin—skin cancer	0.00121	0.00356	CcSEcCtD
Raloxifene—Chest pain—Imiquimod—skin cancer	0.0012	0.00355	CcSEcCtD
Raloxifene—Arthralgia—Imiquimod—skin cancer	0.0012	0.00355	CcSEcCtD
Raloxifene—Myalgia—Imiquimod—skin cancer	0.0012	0.00355	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.0012	0.00353	CcSEcCtD
Raloxifene—Bronchitis—Temozolomide—skin cancer	0.00117	0.00345	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00117	0.00345	CcSEcCtD
Raloxifene—ESR2—lymphoid tissue—skin cancer	0.00116	0.0287	CbGeAlD
Raloxifene—Hypoaesthesia—Bleomycin—skin cancer	0.00115	0.00339	CcSEcCtD
Raloxifene—Infection—Imiquimod—skin cancer	0.00115	0.00338	CcSEcCtD
Raloxifene—Shock—Imiquimod—skin cancer	0.00114	0.00335	CcSEcCtD
Raloxifene—Nervous system disorder—Imiquimod—skin cancer	0.00113	0.00334	CcSEcCtD
Raloxifene—Skin disorder—Imiquimod—skin cancer	0.00112	0.00331	CcSEcCtD
Raloxifene—ESR2—female reproductive system—skin cancer	0.00112	0.0276	CbGeAlD
Raloxifene—Hyperhidrosis—Imiquimod—skin cancer	0.00112	0.00329	CcSEcCtD
Raloxifene—HTR2B—skin of body—skin cancer	0.00111	0.0274	CbGeAlD
Raloxifene—Weight increased—Temozolomide—skin cancer	0.00111	0.00327	CcSEcCtD
Raloxifene—Pneumonia—Temozolomide—skin cancer	0.00109	0.00322	CcSEcCtD
Raloxifene—ESR1—connective tissue—skin cancer	0.00109	0.0268	CbGeAlD
Raloxifene—Depression—Temozolomide—skin cancer	0.00108	0.00319	CcSEcCtD
Raloxifene—AOX1—female reproductive system—skin cancer	0.00108	0.0266	CbGeAlD
Raloxifene—Flushing—Bleomycin—skin cancer	0.00107	0.00316	CcSEcCtD
Raloxifene—Body temperature increased—Vemurafenib—skin cancer	0.00107	0.00316	CcSEcCtD
Raloxifene—Pharyngitis—Dactinomycin—skin cancer	0.00107	0.00315	CcSEcCtD
Raloxifene—Urinary tract infection—Temozolomide—skin cancer	0.00105	0.00311	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00105	0.0031	CcSEcCtD
Raloxifene—Insomnia—Imiquimod—skin cancer	0.00104	0.00308	CcSEcCtD
Raloxifene—ESR1—epithelium—skin cancer	0.00103	0.0255	CbGeAlD
Raloxifene—Sinusitis—Temozolomide—skin cancer	0.00102	0.003	CcSEcCtD
Raloxifene—Dyspepsia—Imiquimod—skin cancer	0.00102	0.003	CcSEcCtD
Raloxifene—SIGMAR1—mammalian vulva—skin cancer	0.00101	0.025	CbGeAlD
Raloxifene—Pneumonia—Fluorouracil—skin cancer	0.00101	0.00297	CcSEcCtD
Raloxifene—Hot flush—Docetaxel—skin cancer	0.001	0.00295	CcSEcCtD
Raloxifene—Flushing—Dactinomycin—skin cancer	0.000999	0.00295	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Imiquimod—skin cancer	0.000997	0.00294	CcSEcCtD
Raloxifene—Menopausal symptoms—Docetaxel—skin cancer	0.000992	0.00293	CcSEcCtD
Raloxifene—Pain—Imiquimod—skin cancer	0.000987	0.00291	CcSEcCtD
Raloxifene—Urinary tract infection—Fluorouracil—skin cancer	0.000972	0.00287	CcSEcCtD
Raloxifene—Conjunctivitis—Fluorouracil—skin cancer	0.000972	0.00287	CcSEcCtD
Raloxifene—Hypoaesthesia—Temozolomide—skin cancer	0.000969	0.00286	CcSEcCtD
Raloxifene—Pharyngitis—Temozolomide—skin cancer	0.000967	0.00285	CcSEcCtD
Raloxifene—Urinary tract disorder—Temozolomide—skin cancer	0.000962	0.00284	CcSEcCtD
Raloxifene—Oedema peripheral—Temozolomide—skin cancer	0.000959	0.00283	CcSEcCtD
Raloxifene—Connective tissue disorder—Temozolomide—skin cancer	0.000957	0.00282	CcSEcCtD
Raloxifene—Urethral disorder—Temozolomide—skin cancer	0.000955	0.00282	CcSEcCtD
Raloxifene—Gastrointestinal pain—Imiquimod—skin cancer	0.000944	0.00278	CcSEcCtD
Raloxifene—Sinusitis—Fluorouracil—skin cancer	0.000938	0.00277	CcSEcCtD
Raloxifene—ESR2—head—skin cancer	0.000936	0.0231	CbGeAlD
Raloxifene—Diarrhoea—Vemurafenib—skin cancer	0.000926	0.00273	CcSEcCtD
Raloxifene—Migraine—Docetaxel—skin cancer	0.000921	0.00272	CcSEcCtD
Raloxifene—Abdominal pain—Imiquimod—skin cancer	0.000913	0.00269	CcSEcCtD
Raloxifene—Body temperature increased—Imiquimod—skin cancer	0.000913	0.00269	CcSEcCtD
Raloxifene—Cardiac disorder—Temozolomide—skin cancer	0.000904	0.00267	CcSEcCtD
Raloxifene—Flushing—Temozolomide—skin cancer	0.000904	0.00267	CcSEcCtD
Raloxifene—Rhinitis—Fluorouracil—skin cancer	0.0009	0.00265	CcSEcCtD
Raloxifene—Dizziness—Vemurafenib—skin cancer	0.000895	0.00264	CcSEcCtD
Raloxifene—Hypoaesthesia—Fluorouracil—skin cancer	0.000893	0.00263	CcSEcCtD
Raloxifene—Pharyngitis—Fluorouracil—skin cancer	0.000891	0.00263	CcSEcCtD
Raloxifene—Angiopathy—Temozolomide—skin cancer	0.000884	0.00261	CcSEcCtD
Raloxifene—CYP19A1—female reproductive system—skin cancer	0.000883	0.0218	CbGeAlD
Raloxifene—Cough—Bleomycin—skin cancer	0.000877	0.00259	CcSEcCtD
Raloxifene—HTR2B—female reproductive system—skin cancer	0.000866	0.0214	CbGeAlD
Raloxifene—Vomiting—Vemurafenib—skin cancer	0.000861	0.00254	CcSEcCtD
Raloxifene—Chest pain—Bleomycin—skin cancer	0.000856	0.00252	CcSEcCtD
Raloxifene—Myalgia—Bleomycin—skin cancer	0.000856	0.00252	CcSEcCtD
Raloxifene—Rash—Vemurafenib—skin cancer	0.000854	0.00252	CcSEcCtD
Raloxifene—Dermatitis—Vemurafenib—skin cancer	0.000853	0.00252	CcSEcCtD
Raloxifene—Headache—Vemurafenib—skin cancer	0.000848	0.0025	CcSEcCtD
Raloxifene—Breast disorder—Docetaxel—skin cancer	0.000846	0.0025	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000843	0.00249	CcSEcCtD
Raloxifene—Infection—Bleomycin—skin cancer	0.000815	0.0024	CcSEcCtD
Raloxifene—Nausea—Vemurafenib—skin cancer	0.000804	0.00237	CcSEcCtD
Raloxifene—Thrombocytopenia—Bleomycin—skin cancer	0.000803	0.00237	CcSEcCtD
Raloxifene—Myalgia—Dactinomycin—skin cancer	0.000798	0.00235	CcSEcCtD
Raloxifene—ESR1—lymphoid tissue—skin cancer	0.000796	0.0196	CbGeAlD
Raloxifene—Diarrhoea—Imiquimod—skin cancer	0.00079	0.00233	CcSEcCtD
Raloxifene—ESR1—female reproductive system—skin cancer	0.000767	0.0189	CbGeAlD
Raloxifene—Dizziness—Imiquimod—skin cancer	0.000764	0.00225	CcSEcCtD
Raloxifene—Vertigo—Temozolomide—skin cancer	0.000762	0.00225	CcSEcCtD
Raloxifene—Infection—Dactinomycin—skin cancer	0.00076	0.00224	CcSEcCtD
Raloxifene—Thrombocytopenia—Dactinomycin—skin cancer	0.000749	0.00221	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000747	0.0022	CcSEcCtD
Raloxifene—Cough—Temozolomide—skin cancer	0.00074	0.00218	CcSEcCtD
Raloxifene—CYP19A1—head—skin cancer	0.000738	0.0182	CbGeAlD
Raloxifene—Weight increased—Docetaxel—skin cancer	0.000736	0.00217	CcSEcCtD
Raloxifene—Vomiting—Imiquimod—skin cancer	0.000734	0.00217	CcSEcCtD
Raloxifene—Rash—Imiquimod—skin cancer	0.000728	0.00215	CcSEcCtD
Raloxifene—Dermatitis—Imiquimod—skin cancer	0.000727	0.00215	CcSEcCtD
Raloxifene—CYP2B6—skin of body—skin cancer	0.000726	0.0179	CbGeAlD
Raloxifene—Pneumonia—Docetaxel—skin cancer	0.000726	0.00214	CcSEcCtD
Raloxifene—HTR2B—head—skin cancer	0.000724	0.0178	CbGeAlD
Raloxifene—Headache—Imiquimod—skin cancer	0.000723	0.00213	CcSEcCtD
Raloxifene—Myalgia—Temozolomide—skin cancer	0.000722	0.00213	CcSEcCtD
Raloxifene—Arthralgia—Temozolomide—skin cancer	0.000722	0.00213	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000717	0.00211	CcSEcCtD
Raloxifene—Pain—Bleomycin—skin cancer	0.000701	0.00207	CcSEcCtD
Raloxifene—Conjunctivitis—Docetaxel—skin cancer	0.000701	0.00207	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000697	0.00206	CcSEcCtD
Raloxifene—Infection—Temozolomide—skin cancer	0.000687	0.00203	CcSEcCtD
Raloxifene—Nausea—Imiquimod—skin cancer	0.000686	0.00202	CcSEcCtD
Raloxifene—Nervous system disorder—Temozolomide—skin cancer	0.000679	0.002	CcSEcCtD
Raloxifene—Thrombocytopenia—Temozolomide—skin cancer	0.000677	0.002	CcSEcCtD
Raloxifene—Skin disorder—Temozolomide—skin cancer	0.000672	0.00198	CcSEcCtD
Raloxifene—Hyperhidrosis—Temozolomide—skin cancer	0.000669	0.00197	CcSEcCtD
Raloxifene—Chest pain—Fluorouracil—skin cancer	0.000665	0.00196	CcSEcCtD
Raloxifene—Myalgia—Fluorouracil—skin cancer	0.000665	0.00196	CcSEcCtD
Raloxifene—ESR2—lymph node—skin cancer	0.000656	0.0162	CbGeAlD
Raloxifene—Pain—Dactinomycin—skin cancer	0.000654	0.00193	CcSEcCtD
Raloxifene—Rhinitis—Docetaxel—skin cancer	0.000649	0.00192	CcSEcCtD
Raloxifene—Body temperature increased—Bleomycin—skin cancer	0.000648	0.00191	CcSEcCtD
Raloxifene—Hypoaesthesia—Docetaxel—skin cancer	0.000644	0.0019	CcSEcCtD
Raloxifene—Pharyngitis—Docetaxel—skin cancer	0.000643	0.0019	CcSEcCtD
Raloxifene—ESR1—head—skin cancer	0.000641	0.0158	CbGeAlD
Raloxifene—Urinary tract disorder—Docetaxel—skin cancer	0.00064	0.00189	CcSEcCtD
Raloxifene—Oedema peripheral—Docetaxel—skin cancer	0.000638	0.00188	CcSEcCtD
Raloxifene—Connective tissue disorder—Docetaxel—skin cancer	0.000636	0.00188	CcSEcCtD
Raloxifene—Urethral disorder—Docetaxel—skin cancer	0.000635	0.00187	CcSEcCtD
Raloxifene—Infection—Fluorouracil—skin cancer	0.000633	0.00187	CcSEcCtD
Raloxifene—CYP2C8—female reproductive system—skin cancer	0.000632	0.0156	CbGeAlD
Raloxifene—AOX1—lymph node—skin cancer	0.000631	0.0156	CbGeAlD
Raloxifene—Musculoskeletal discomfort—Temozolomide—skin cancer	0.00063	0.00186	CcSEcCtD
Raloxifene—Insomnia—Temozolomide—skin cancer	0.000626	0.00185	CcSEcCtD
Raloxifene—Gastrointestinal pain—Dactinomycin—skin cancer	0.000626	0.00185	CcSEcCtD
Raloxifene—Nervous system disorder—Fluorouracil—skin cancer	0.000625	0.00184	CcSEcCtD
Raloxifene—Thrombocytopenia—Fluorouracil—skin cancer	0.000624	0.00184	CcSEcCtD
Raloxifene—Dyspepsia—Temozolomide—skin cancer	0.000609	0.0018	CcSEcCtD
Raloxifene—Abdominal pain—Dactinomycin—skin cancer	0.000605	0.00178	CcSEcCtD
Raloxifene—Body temperature increased—Dactinomycin—skin cancer	0.000605	0.00178	CcSEcCtD
Raloxifene—Flushing—Docetaxel—skin cancer	0.000601	0.00177	CcSEcCtD
Raloxifene—Cardiac disorder—Docetaxel—skin cancer	0.000601	0.00177	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Temozolomide—skin cancer	0.000597	0.00176	CcSEcCtD
Raloxifene—Pain—Temozolomide—skin cancer	0.000592	0.00175	CcSEcCtD
Raloxifene—CYP2B6—lymphoid tissue—skin cancer	0.000588	0.0145	CbGeAlD
Raloxifene—Angiopathy—Docetaxel—skin cancer	0.000588	0.00173	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000581	0.00171	CcSEcCtD
Raloxifene—Insomnia—Fluorouracil—skin cancer	0.000577	0.0017	CcSEcCtD
Raloxifene—CYP2B6—female reproductive system—skin cancer	0.000567	0.014	CbGeAlD
Raloxifene—Gastrointestinal pain—Temozolomide—skin cancer	0.000566	0.00167	CcSEcCtD
Raloxifene—Dyspepsia—Fluorouracil—skin cancer	0.000561	0.00166	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Fluorouracil—skin cancer	0.00055	0.00162	CcSEcCtD
Raloxifene—Body temperature increased—Temozolomide—skin cancer	0.000547	0.00161	CcSEcCtD
Raloxifene—Abdominal pain—Temozolomide—skin cancer	0.000547	0.00161	CcSEcCtD
Raloxifene—Pain—Fluorouracil—skin cancer	0.000545	0.00161	CcSEcCtD
Raloxifene—Muscle spasms—Docetaxel—skin cancer	0.000542	0.0016	CcSEcCtD
Raloxifene—Diarrhoea—Dactinomycin—skin cancer	0.000523	0.00154	CcSEcCtD
Raloxifene—Vomiting—Bleomycin—skin cancer	0.000522	0.00154	CcSEcCtD
Raloxifene—Rash—Bleomycin—skin cancer	0.000517	0.00153	CcSEcCtD
Raloxifene—Dermatitis—Bleomycin—skin cancer	0.000517	0.00152	CcSEcCtD
Raloxifene—CYP19A1—lymph node—skin cancer	0.000517	0.0127	CbGeAlD
Raloxifene—SIGMAR1—lymph node—skin cancer	0.000508	0.0125	CbGeAlD
Raloxifene—HTR2B—lymph node—skin cancer	0.000507	0.0125	CbGeAlD
Raloxifene—Syncope—Docetaxel—skin cancer	0.000506	0.00149	CcSEcCtD
Raloxifene—Body temperature increased—Fluorouracil—skin cancer	0.000504	0.00149	CcSEcCtD
Raloxifene—Loss of consciousness—Docetaxel—skin cancer	0.000496	0.00146	CcSEcCtD
Raloxifene—Cough—Docetaxel—skin cancer	0.000492	0.00145	CcSEcCtD
Raloxifene—Nausea—Bleomycin—skin cancer	0.000487	0.00144	CcSEcCtD
Raloxifene—Vomiting—Dactinomycin—skin cancer	0.000486	0.00143	CcSEcCtD
Raloxifene—Rash—Dactinomycin—skin cancer	0.000482	0.00142	CcSEcCtD
Raloxifene—Chest pain—Docetaxel—skin cancer	0.00048	0.00142	CcSEcCtD
Raloxifene—Arthralgia—Docetaxel—skin cancer	0.00048	0.00142	CcSEcCtD
Raloxifene—Myalgia—Docetaxel—skin cancer	0.00048	0.00142	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000477	0.00141	CcSEcCtD
Raloxifene—CYP2B6—head—skin cancer	0.000474	0.0117	CbGeAlD
Raloxifene—Diarrhoea—Temozolomide—skin cancer	0.000473	0.0014	CcSEcCtD
Raloxifene—Dizziness—Temozolomide—skin cancer	0.000458	0.00135	CcSEcCtD
Raloxifene—Infection—Docetaxel—skin cancer	0.000457	0.00135	CcSEcCtD
Raloxifene—Nausea—Dactinomycin—skin cancer	0.000454	0.00134	CcSEcCtD
Raloxifene—Shock—Docetaxel—skin cancer	0.000453	0.00134	CcSEcCtD
Raloxifene—Nervous system disorder—Docetaxel—skin cancer	0.000451	0.00133	CcSEcCtD
Raloxifene—Thrombocytopenia—Docetaxel—skin cancer	0.000451	0.00133	CcSEcCtD
Raloxifene—ESR1—lymph node—skin cancer	0.000449	0.0111	CbGeAlD
Raloxifene—Skin disorder—Docetaxel—skin cancer	0.000447	0.00132	CcSEcCtD
Raloxifene—Vomiting—Temozolomide—skin cancer	0.00044	0.0013	CcSEcCtD
Raloxifene—Rash—Temozolomide—skin cancer	0.000436	0.00129	CcSEcCtD
Raloxifene—Diarrhoea—Fluorouracil—skin cancer	0.000436	0.00129	CcSEcCtD
Raloxifene—Dermatitis—Temozolomide—skin cancer	0.000436	0.00129	CcSEcCtD
Raloxifene—Headache—Temozolomide—skin cancer	0.000433	0.00128	CcSEcCtD
Raloxifene—CYP3A4—female reproductive system—skin cancer	0.000428	0.0106	CbGeAlD
Raloxifene—Dizziness—Fluorouracil—skin cancer	0.000422	0.00124	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000419	0.00124	CcSEcCtD
Raloxifene—Insomnia—Docetaxel—skin cancer	0.000416	0.00123	CcSEcCtD
Raloxifene—Nausea—Temozolomide—skin cancer	0.000411	0.00121	CcSEcCtD
Raloxifene—Vomiting—Fluorouracil—skin cancer	0.000405	0.0012	CcSEcCtD
Raloxifene—Dyspepsia—Docetaxel—skin cancer	0.000405	0.00119	CcSEcCtD
Raloxifene—Rash—Fluorouracil—skin cancer	0.000402	0.00119	CcSEcCtD
Raloxifene—Dermatitis—Fluorouracil—skin cancer	0.000402	0.00118	CcSEcCtD
Raloxifene—Headache—Fluorouracil—skin cancer	0.000399	0.00118	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Docetaxel—skin cancer	0.000397	0.00117	CcSEcCtD
Raloxifene—Pain—Docetaxel—skin cancer	0.000393	0.00116	CcSEcCtD
Raloxifene—Nausea—Fluorouracil—skin cancer	0.000379	0.00112	CcSEcCtD
Raloxifene—Gastrointestinal pain—Docetaxel—skin cancer	0.000376	0.00111	CcSEcCtD
Raloxifene—Body temperature increased—Docetaxel—skin cancer	0.000364	0.00107	CcSEcCtD
Raloxifene—Abdominal pain—Docetaxel—skin cancer	0.000364	0.00107	CcSEcCtD
Raloxifene—Diarrhoea—Docetaxel—skin cancer	0.000315	0.000929	CcSEcCtD
Raloxifene—Dizziness—Docetaxel—skin cancer	0.000304	0.000897	CcSEcCtD
Raloxifene—Vomiting—Docetaxel—skin cancer	0.000293	0.000863	CcSEcCtD
Raloxifene—Rash—Docetaxel—skin cancer	0.00029	0.000856	CcSEcCtD
Raloxifene—Dermatitis—Docetaxel—skin cancer	0.00029	0.000855	CcSEcCtD
Raloxifene—Headache—Docetaxel—skin cancer	0.000288	0.00085	CcSEcCtD
Raloxifene—Nausea—Docetaxel—skin cancer	0.000273	0.000806	CcSEcCtD
